Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
All content for FAACT's Roundtable is the property of FAACT's Roundtable Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
Ep. 250: Accommodations in the Workplace and Public Entities
FAACT's Roundtable
18 minutes
2 months ago
Ep. 250: Accommodations in the Workplace and Public Entities
Food allergy accommodations don’t stop at the classroom door—they extend into workplaces, public spaces, and even stadiums. But what rights do you actually have? Today, we’re joined by FAACT’s General Counsel, Amelia Smith, JD, to break it all down and help you understand your civil rights. Resources to keep you in the know: FAACT's Accommodations Resource CenterFAACT's Civil Rights Advocacy Resource CenterFAACT's Local ResourcesContact Amelia Smith, JD: Amelia.Smith@FoodAllergyAwareness.orgY...
FAACT's Roundtable
Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
